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Hepatitis B and A account for considerable morbidity and
mortality worldwide. Immunization is the most effective
means of preventing hepatitis B and A. However, the immune
response to both hepatitis vaccines seems to be reduced in
HIV-infected subjects. The aim of this review was to analyze
the immunogenicity, safety, long-term protection and current
recommendations of hepatitis B and A vaccination among
HIV-infected adults. The factors most frequently associated
with a deﬁcient level of anti-HBs or IgG anti-HAV after
vaccination are those related to immunosuppression (CD4
level and HIV RNA viral load) and to the frequency of
administration and/or the amount of antigenic load per dose.
The duration of the response to both HBV and HAV vaccines
is associated with suppression of the viral load at vaccination
and, in the case of HBV vaccination, with a higher level of
antibodies after vaccination. In terms of safety, there is no
evidence of more, or different, adverse effects compared with
HIV-free individuals. Despite literature-based advice on the
administration of alternative schedules, revaccination after
the failure of primary vaccination, and the need for periodic
re-evaluation of antibody levels, few ﬁrm recommendations
are found in the leading guidelines.
Introduction
With the advent of effective antiretroviral treatment, life
expectancy for people living with the human immunodeficiency
virus (HIV) is now approaching that of the general population.
Consequently, the relative importance of non-AIDS-related mor-
bidities has increased. After AIDS-related deaths and non-AIDS-
defining cancers, liver disease is the third underlying cause of
death in people living with HIV.1
Viral hepatitis is a major global health issue affecting nearly
400 million people worldwide.2 Due to shared modes of trans-
mission, a high proportion of adults at risk for HIV infection are
also at risk for hepatitis B virus (HBV) infection. Reciprocal
interactions between HIV and HBV lead to an increased risk for
severe, life-threatening complications.3 Hepatitis A virus (HAV)
infection, mainly transmitted through the faecal-oral route, can
cause mild-to-severe illness but does not lead to chronic infec-
tion.4 HIV-infected people may experience prolonged HAV vire-
mia, which has important public health implications for
transmission within the community.5 Numerous studies have
searched for new strategies to improve response rates after HBV
vaccination and improve long-term antibody persistence: higher
hepatitis B vaccine doses and/or prolongation of the vaccination
schedule, use of the intradermal route, and adding vaccine adju-
vant. The immunogenicity of hepatitis A vaccines in HIV-
infected adults has also been assessed in several studies.6-8
The objective of this review was to describe the state-of-the art
of HBV and HAV vaccination in HIV-infected adults. As part of
this update, a comprehensive literature review of seroprotection
rates and factors associated with the immunogenicity to HBV
and HAV vaccination in HIV-infected adults in the highly active
antiretroviral therapy (HAART) era was made. This new review
updates that published on the same topic in 2012:8 the results of
studies published until 2015, including both clinical trials and all
observational studies that complied with the selection criteria of
the search strategy used, have been included (Fig. 1).
HBV Vaccination in HIV-Infected Subjects
HBV/HIV co-infection: epidemiology and natural history
The introduction of effective vaccination programs in many
countries has resulted in a significant decrease in the incidence of
HBV infection, although it remains an important cause of mor-
bidity and mortality worldwide.9 The predominant mode of
transmission of HBV varies between different geographical areas.
Perinatal infection is the predominant mode of transmission in
areas of high prevalence, horizontal transmission, particularly in
early childhood, accounts for most cases of chronic HBV infec-
tion in areas of intermediate prevalence, while unprotected sexual
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intercourse and intravenous drug use in adults are the major
transmission routes in areas of low prevalence.10
HIV infection shares the above-mentioned routes of transmis-
sion, but is about 100-times less infectious. Consequently, in
some settings, up to 2 thirds of all HIV-infected people have a
blood marker of past or present HBV infection.11,12 With a
global prevalence of coinfection of around 10%, among HIV-
infected individuals, estimates of chronic HBV infection in
HIV-infected subjects are much lower in western countries, but
are still remarkable, being up to 20-times higher than in the gen-
eral population.13-15 In areas of low endemicity, such as North
America, Australia and Western Europe, the prevalence of
chronic coinfection is around 5–7% in HIV-infected individu-
als.15 In countries with intermediate and high HBV endemicity,
coinfection rates range from 10 to 20%.16-18
HIV appears to be a risk factor for the reactivation of HBV
infection in patients who have developed HBV surface antibod-
ies, especially those with severe immunodeficiency.11,19
Although, the degree of HIV-induced immunosuppression does
not seem to correlate well with liver injury,20 a higher risk of
chronicity after acute HBV infection has been shown21 as have
increased carriage rates and greater viral replication.20,22,23
Higher levels of HBV replication not only increase the risk of
HBV transmission but also result in more-rapid progression of
liver fibrosis, with a higher risk of cirrhosis and end-stage liver
disease, especially in patients with low CD4C cell nadir counts.12
Conversely, there is less evidence on the effects of HBV on the
natural history of HIV progression.24 Prospective studies have
shown an increased risk of progression to AIDS in patients with
HBV coinfection.25,26 It also seems that lower CD4C cell counts
may increase the risk for hepatocellular carcinoma (HCC) in
people living with HIV, an effect that was particularly evident for
HBV-related HCC in non-injecting drug users in the case-con-
trol study by Clifford et al.27
Hepatitis B vaccines for adults
The first recombinant HBV vaccine
was introduced in 1986 and has gradu-
ally replaced the plasma-derived HBV
vaccines that became commercially
available in 1982. The recombinant vac-
cine contains more than 95% HBsAg
protein (5 to 40 mg/mL); yeast-derived
proteins may constitute up to 5% of the
final product but no yeast DNA is
detectable in the vaccine. Vaccine
HBsAg is adsorbed to aluminum
hydroxide or aluminum phosphate.28,29
Currently-available US. Food and Drug
Administration (FDA)-approved HBV
vaccines for adults include: Engerix-B
(GlaxoSmithKline, Belgium), contain-
ing 20 mg HBsAg; Recombivax HB
(Merck, USA) containing 10 mg
HBsAg; and the combined HAV C
HBV Twinrix (GlaxoSmithKline, Bel-
gium), containing 20 mg HBsAg and
720 ELISA units of inactivated HAV.30 The European Medi-
cines Agencies (EMA) only shares with the FDA the approval of
Twinrix. The two non-combined HBV vaccines approved by the
EMA that differ from those approved by the FDA are: HBVax-
PRO (Sanofi Pasteur MSD, Lyon) containing 10 or 40 mg
HBsAg (for use only in predialysis and dialysis patients aged 
18 years), and Fendrix (GlaxoSmithKline, Belgium), containing
20 mg HBsAg and adjuvanted by AS043, which is only indicated
in patients with kidney disease.31 Currently, there are no specific
hepatitis vaccines or special indications for immunocompromised
subjects with HIV in the summary of product characteristics of
the licensed hepatitis vaccines.
Hepatitis B vaccines: efficacy and safety
The protective efficacy of HBV vaccination is related to the
induction of anti-HBs antibodies, but also involves the induction
of memory T-cells. An anti-HBs concentration of  10 IU/L
measured 1–3 months after administration of the last dose of the
primary vaccination series is considered a reliable marker of pro-
tection against infection.28,32 The primary 3-dose vaccine series
induces protective antibody concentrations in >95% of healthy
children, adolescents and adults. 28,33-35 The protection provided
by 3 or 4 doses of monovalent HB vaccine persists for at least 2
decades in the great majority of immunocompetent individuals.36
The HBV vaccine is well-tolerated by newborns, children and
adults, with injection site pain being the most common reported
adverse event.37-41 The WHO Global Advisory Committee on
Vaccine Safety (GACVS) has endorsed the excellent safety profile
of the HBV vaccine.28
Immunological response after HBV vaccination in HIV-
infected adults: associated factors
A diminished response to HBV vaccination among immuno-
compromised adults has repeatedly been shown.42-44 This
Figure 1. Search strategy and selection criteria of articles included in the review.
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includes HIV-infected subjects.45 As shown in Table 1, the
immune response to a 20 mg HBsAg dose embedded within the
standard schedule of HBV vaccination (0, 1 and 6 months) in
HIV-infected adults is suboptimal, ranging from 34.0% to
88.6%.46-54 Of the 9 studies evaluating the response after 3 doses
of 20 mg HBsAg that were included in our review, the results of
the 3 randomized clinical trials (RCT) included (all with >80%
subjects on HAART) showed wide disparities (34.0% to
88.6%).46,52,53 Observational studies assessing the effects of 3
doses of 20 mg HBsAg found seroconversion rates of between
34.7 and 47.2% after vaccination.47-51 The same schedule of 3
doses, but using 10 mg HBsAg, was evaluated in a retrospective
study with a very-high proportion of subjects on HAART which
found a seroconversion rate of only 17.5%,55 the worst reported
until now. Half of the patients included in the non-inferiority
RCT by de Vries Sluijs et al., after receiving either one (10 mg)
or 2 (10 mg and 20 mg) series at 0,1 and 2 months,56 and
61.5% of those in the RCT by Cornejo-Juarez et al.,57 responded
to 3 doses of 10 mg HBsAg. These studies used 10 mg of HBvax-
Pro, which is equivalent to 20 mg of Engerix B.
Four prospective studies evaluated the 0, 1 and 6 months
schedule with 40 mg HBsAg per HBV vaccine shot.46,57-59 The
proportion of subjects who seroconverted ranged between 46.9%
in the RCT by Fonseca et al.46 and 63.8% in the observational
study by Veiga et al.59 Four other studies evaluated the immuno-
genicity after 4 vaccine doses at 0, 1, 2 and 6 months (accelerated
schedule);52,53,60,61 a protective antibody response was observed
in 89.4% and 90.8% of subjects receiving 4 doses of 40 mg in 2
observational studies.60,61 The RCT by Launay et al. also showed
that both the 4 40 mg-intramuscular and the 4 4 mg-intradermal
schedules improved the serological response (82.1% and 77.1%,
respectively), compared with the standard 20 mg-intramuscular
HBV vaccine schedule (64.5%).52 The fourth and most recent
study, a RCT, found no statistically significant differences in the
proportion of responders between the standard schedule (88.6%)
and 20 or 40 mg HBsAg in a 4 dose-schedule (93.2% and
95.5%, respectively).53 Finally, 3 doses of a rapidly-accelerated
schedule at 0, 1, and 2–3 weeks were evaluated in one RCT, and
found that 38.7% of subjects developed seroprotection with the
10mg dose of HBVaxPro,56 while a retrospective study using
20mg of HBsAg found a seroprotection rate of 50%.62
Two of the studies included in our review evaluated the use
of adjuvants as stimulators of immunogenicity of the vaccine.
Twenty mg of recombinant human granulocyte-macrophage
colony-stimulating factor (rhGM-CSF) was administered con-
comitantly with the first vaccine dose of 40 mg HBsAg,
increasing the immunogenicity of the recombinant HBV vac-
cine (72.5% vs. 60% in controls) after a 3-dose schedule.58
Conversely, a more-recent RCT did not confirm greater pro-
tective immunity in patients receiving 250 mg GM-CSF as an
adjuvant to a 40 mg-accelerated schedule at 0, 1 and 3 months
(52.4% vs. 65.2% in controls). 63
Studies have also evaluated the immune response of a second
schedule after the failure of a primary series of at least 3 doses of
HBV vaccine. A 20mg HBV rescue vaccination at 0, 1 and
6 months after the primary series with 3 20mg HBsAg doses at 0,
1 to 3 and 6 months was evaluated in a prospective observational
study, and achieved a seroconversion rate of 83.3% in patients
completing the 2 schedules.64 Two retrospective studies evalu-
ated the response in subjects receiving 40mg HBsAg rescue vacci-
nation at 0, 1, and 6 mo after failure with primary vaccination
with the same schedule. They found similar protection rates
(66.7% and 70%) in subjects vaccinated with 6 doses. 51,54
Another retrospective study found a better outcome, with a
81.5% of subjects receiving a rescue schedule of 40mg at 0, 1 and
2 months after failure with a primary standard schedule at 20mg
per dose.65
The administration of 4 vaccine doses at 0, 1, 2 and 6 months
(accelerated schedule), whether of 20 or 40 mg, generally confers
a better response to the vaccine. Rescue vaccination with one or
more doses also seems to be effective in raising the rate of res-
ponders in vaccinate HIV subjects. Intradermal administration
and the use of the GM-CSF adjuvant have been associated with
the level of seroprotection after vaccination, although the evi-
dence remains poor. There is also insufficient evidence on the
administration of ultra-rapid schedules to consider this strategy
as an acceptable option in HIV-infected individuals.
Undetectable or minimum HIV RNA viral load and a
higher CD4C cell count at baseline are the factors most-fre-
quently associated with a successful response to HBV vaccina-
tion in both RCT and observational studies.47-55,57,59-62,64,66
The CD4C cell count cutoffs most-frequently associated with
a better response were >400, >300 and >200 cells/mm.3
Given that the populations analyzed in the studies were
widely treated with HAART, and that the combination of
antiretroviral drugs can maintain viral loads at low levels for
long periods, patient treatment, for which associations were
rarely found in multivariate analyses should play an impor-
tant role in the response to HBV vaccination through HIV
RNA viral suppression.50,54 Female sex57,64,66,67 and younger
age47,48,51,52 were also repeatedly found to be independent
factors for vaccine responsiveness. African-American ethnic-
ity,48 alcohol abuse,48 and tobacco smoking,52 have occasion-
ally been associated with a lack of response.
The response to vaccination may to be related as much to
direct dysfunction of the memory B cells as to indirect dys-
function due to activation of regulatory T cells and the conse-
quent apoptosis of B cells, which is more frequent in persons
immunocompromised due to HIV.68-70 Seroprotective anti-
body formation after vaccination is reduced with increasing
age, when the immune state is more affected. With age, the
na€ıve T cell pool is reduced, because, on encounteringtheir
cognate antigen, na€ıve T cells are primed, acquire a memory
phenotype and ultimately die by apoptosis.This physiologic
loss of T cells is slow because bursts of immune activation are
relieved with periods of relative rest. In HIV infection, an
identical process occurs but at a faster pace because of the
continuous attendance of pathogens.71
The main factors associated with the individual lack of
response are those related to immunological deterioration. The
relationship between the lack of response and sex remains
unclear.
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Long-term persistence of protective levels of anti-HBs
The duration of protection induced by the hepatitis B vaccine
in immunocomptent individuals is not widely understood. Anti-
HBs titres decrease over time and can fall below protective con-
centrations. In HIV-infected subjects this process goes faster.7
Few studies have assessed the persistance of anti-HBs 1 year
after the last shot in HIV infected adults. In a prospective study,
65 HIV-infected patients received 40 mg HBsAg at 0, 1, and
2 months.66 In non-responders to the initial immunization, 1–3
boosters were administered. The response rate was 60% after pri-
mary vaccination and 89.2% after boosters, with antibody titres
significantly lower in non-responders than in responders to pri-
mary vaccination. However, 12 and 24 months after the last vac-
cination, only 70.6% and 32.7% of responders, respectively, had
persistence of protective anti-HBs titres ( 10 IU/L). Persistence
of anti-HBs titres was significantly-associated with antibody titres
after immunization. A retrospective chart review by Kim et al.
included HIV-infected patients who received the 40 mg HBsAg
rescue vaccination at 0, 1, and 2-month intervals after failure
with the conventional HBV vaccination series.65 Of 54 HIV-
infected patients who received the rescue vaccination schedule,
44 (81.5%) achieved protective anti-HB titres. Of the 33 patients
whose anti-HB titres were evaluated 12 months later, 19 (57.6%)
had persistent protective anti-HB titres. An undetectable HIV
viral load at baseline and follow-up was associated with the pres-
ence of protective antibody rates.
Results of 2 observational studies assessing the long-term
response to hepatitis B vaccination are of interest. In one study,
after a median follow-up of 43 months, 111 of the 152 partici-
pants (73%) maintained protective levels of anti-HBs. In this
case, HIV RNA suppression at vaccination was also associated
with persistence of protective levels of anti-HBs.72 In a 5-year
prospective study by Lopes et al.,73 the durability of an effective
anti-HBs level appeared to be significantly-associated with a
higher level of antibody titres after primary immunization. The
mean time to loss of effective anti-HBs titres was 2.0, 3.7 and
4.4 y for patients with anti-HBs titres of 10–100 IU/L, >100–
1000 IU/L and >1000 IU/L respectively at primary vaccination.
Sixty-eight of the 155 initial responders (43.9%) mantained sero-
protection rates at the last determination.
B-cell dysfunction in HIV, which is more frequent in patients
with detectable viral loads and low levels of CD4C lymphocytes,
is also related to the loss of memory and undetectable levels of
anti-HBs over time.74
Safety of HBV vaccination in HIV-infected adults
HBV vaccination of HIV-infected and non-HIV infected sub-
jects shows a similar safety profile. A recent RCT using 20 mg
HBsAg in an accelerated or standard schedule, or 40 mg in an
accelerated schedule found that the most-common adverse events
were pain at the injection site (42.4%), fatigue (10.6%) and
swelling at the injection site (10.1%). Pain at the injection site
was significantly-more common in the 40 mg group. There were
no serious adverse events (SAEs) related to any vaccination
schedule.53
One RCT52 compared the safety and immunogenicity of 4
intramuscular 40 mg dose and 4 intradermal 4 mg regimens vs.
the standard intramuscular 20 mg HBV vaccine regimen. This
study found the most common adverse events were very similar
to those found by the previously-mentioned study. Patients in
the intramuscular (i.m.) 40£4 group experienced a higher rate of
fever, nausea, and edema, and patients in the intradermal (i.d.)
40£4 group experienced a higher proportion of local adverse
reactions (except pain, which was less frequent) than patients in
the i.m. 20£3 group. Only one serious adverse event (severe
cytolysis) possibly related to the vaccine was reported in the i.m.
40£4 group. A higher incidence of injection site adverse events
was reported in the i.d. 40£4 group compared with the i.m.
20£3 group. The proportion of solicited systemic reactions was
generally similar between the 3 groups. However, the RCT by
Fonseca et al.46 found more reported adverse events in the 40 mg
HBsAg- than in the 20 mg HBsAg-group (both administered at
0, 1 and 6 months). In this case, the most common adverse
events were pain at the injection site, headache and fever.
HBV vaccination coverage in HIV-infected population
Coverage of hepatitis B vaccination depends on the degree of
implementation of international guidelines, scientific societies
and expert panels recommendations used by the different
Table 2. Key issues in hepatitis B vaccination in adults living with HIV
 Viral hepatitis-related liver failure remains the most common main speciﬁc cause of liver-related deaths in people living with HIV.
 Reciprocal interactions between HIV and HBV leads to an increased risk for serious, life-threatening complications.
 Higher levels of HBV replication not only increase the risk of HBV transmission but also result in faster progression of liver ﬁbrosis, with a higher risk of
cirrhosis and end-stage liver disease, especially in patients with low CD4C cell nadir counts.
 A diminished response to HBV vaccination in immunocompromised adults has been repeatedly shown. This includes HIV-infected subjects.
 Undetectable or minimum HIV RNA viral load and higher CD4C cell count at baseline are the factors most-frequently associated with a successful response
to HBV vaccination in both RCT and observational studies.
 Younger age and female sex were also repeatedly found to be independent factors for HBV vaccine responsiveness in HIV-infected subjects.
 A higher number of shots and HBsAg dosage have also been shown to play a signiﬁcant role in anti-HBs seroconversion in HIV-infected patients.
 HIV RNA suppression at vaccination has been associated with the persistence of protective levels of anti-HBs.
 HBV vaccination of HIV-infected and non-HIV infected subjects shows a similar safety proﬁle.
 The BHIVA and the US Guidelines for prevention and treatment of opportunistic infections in HIV-Infected adults and adolescents maintain the need for
annual serological testing in immunocompromised individuals who have previously responded after one or 2 series of vaccination.
 Primary vaccination with alternative frequencies of administration, a higher number of doses, a higher concentration of HBsAg per dose, and different
routes of administration have not been recommended by any of the guidelines or institutions mentioned in this review.
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countries. A cross-sectional study was performed in HIV-infected
patients included in a hospital-based cohort in France in 2011:
2,467 patients were included, with a vaccination coverage of
61.9%.75 Factors independently associated with vaccination were
a younger age, male sex, men who have sex with men (MSM),
and follow-up by an experienced physician. In an observational
cohort of over 37,000 HIV-positive individuals attending some
of the largest HIV treatment centers in the UK, seroprotection
rates increased from 42.0% in 1996 to 58.2% in 200976. An
improvement in vaccine coverage and vaccine response rates (as
the mean CD4 count of the cohort increased) could both be
related to this increase in the seroprotected population. A very-
similar overall HBV vaccination coverage was found in a recent
cross-sectional study (57.4%) in southern Brazil.77 The coverage
was lower than that previously reported among HIV-infected
adults (76,9%)78 in southern Brazil. In the mentioned study, sig-
nificant inequalites in coverage rates and antibody reactivity in
favor of patients with better economic status led the authors to
highlight the need for the development of public strategies in
order to increase the availability of healthcare services for poorer
people.
Among HIV infected adults, given a poorer response rate,
prevalence of seroprotection might not be a good proxy for vacci-
nation coverage. In the absence of vaccination data, authors of
the UK and Brazilian studies couldnt be certain whether the
number of people presenting anti-HBs <10 UI/L was due to
failure to vaccinate or to an impaired immune vaccine response
in HIV-positive individuals. Lacking other studies on hepatitis B
vaccination coverages in HIV-infected subjects, it may be said
that, in the studies carried out in UK, France and southern Brazil,
around 40% of those not already infected remained at risk of
HBV infection at the time of the test result.
Current recommendations on hepatitis B vaccination for
HIV-infected patients
The default international recommendation remains the
administration of 3 doses of 20 mg HBsAg at 0, 1 and 6 months.
The US Guidelines for prevention and treatment of opportunis-
tic infections in HIV-Infected adults and adolescents (Recom-
mendations from the CDC, the National Institutes of Health,
and the HIV Medicine Association of the Infectious Diseases
Society of America),79 and the British HIV Association (BHIVA)
Guidelines for the Immunisation of HIV-infected Adults80 both
recommend serologic determination of antibodies one month
and 6–8 weeks, respectively, after administration of the last dose
of vaccine. When concentrations of anti-HBs of 10 IU/L are not
reached after primary vaccination, revaccination may be consid-
ered, according to the CDC’s Pinkbook statements.29 The US
and the European AIDS Clincial Society (EACS) Guidelines also
recommend considering revaccination after primary-schedule
vaccination failure.79,81 The BHIVA Guidelines go further, rec-
ommending rescue vaccination with 3 40 mg doses, given at
monthly intervals.80
In immunocompetent individuals, long-term persistence of
protective levels of anti-HBs after vaccination is variable, and fac-
tors related to the loss of seroprotection are currently under
study.36 In HIV-infected subjects, loss of memory B cells affects
the maintenance of long-term protective titres. In the absence of
indications from the CDC, the WHO, and EACS Guidelines,
when faced with anti-HBs titres falling below the protective level
(10 IU/L), the BHIVA Guidelines maintain the need for annual
serological testing in immunocompromised individuals who have
previously responded after one or 2 series of vaccination.80 The
US Guidelines for prevention and treatment of opportunistic
infections in HIV-Infected adults and adolescents also suggest
yearly assessment for patients with an ongoing risk for HBV
acquisition.79
Primary vaccination with a higher number of doses or a higher
concentration of HBsAg per dose has not been recommended by
any of the previously-mentioned institutions or associations.
Hepatitis A Vaccination in HIV-Infected Subjects
HAV/HIV co-infection: epidemiology and natural history
HAV is the most common form of acute viral hepatitis world-
wide.82 Approximately 1.4 million clinical cases and tens of mil-
lions of HAV infections occur every year, although the number
of infections is probably much higher due to the high percentage
of asymptomatic cases.82 HAV is mainly transmitted by the fae-
cal-oral route and its incidence is related to hygiene and access to
safe water.83 Clinical hepatitis is more frequent in areas of low or
intermediate endemicity (low income countries) and universal
vaccination programs against HAV are only recommended in
these countries.82,83 The prevalence of anti-HAV increases gradu-
ally with age, primarily reflecting declining incidence, changing
Table 3. Key issues in hepatitis A vaccination in adults living with HIV
 After infection, the HAV load is higher, the duration of viremia is longer and faecal excretion is prolonged in the case of concurrent HIV infection.
 The immune response to HAV vaccination is reduced in immunocompromised patients, with seroconversion rates ranging from 48.5% to 93.9%.
 Higher CD4 counts are associated with a better vaccine response. Likewise, low HIV RNA viral loads lead to better vaccine response in HIV-infected adults.
Male sex and HCV co-infection were found to be independent factors for HBV vaccine non-responsiveness in HIV-infected subjects.
 Studies comparing the vaccine response according to whether recipients received 2 or 3 doses of inactivated HAV vaccine found that both the proportion
of responders and the GMT of HAV antibodies were higher after the third dose.
 The duration of protection has been associated with suppressed HIV RNA levels at time of vaccination.
 No serious adverse events are usually reported after HAV vaccination regardless of the number of doses or the immunological status, and vaccination has
no effect on the course of HIV infection.
 The CDC and WHO recommend vaccinating these subjects if any other medical, behavioral, epidemiological or occupational condition is added to HIV
infection. The EACS recommends periodic controls of antibody titres in vaccinated immunocompromised subjects.
 The EACS recommends periodic controls of antibody titres in vaccinated immunocompromised subjects.
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endemicity and, as a result, a lower childhood infection rate over
time.84-87 The estimated case-fatality rate ranges from 0.1% in
children aged <15 y to 2.1% in adults aged > 40 y.88
As the route of infection is faecal-oral, unlike HBV and HIV,
it has been postulated that HAV susceptibility among HIV-
infected subjects should be similar to that of the general popula-
tion89 and thus HIV infection per se would not be a risk factor
for HAV infection. However HIV-infected subjects usually expe-
rience severe, prolonged courses of infectious diseases due to their
impaired immune system: after infection, the HAV load is
higher, the duration of viremia is longer and faecal excretion is
prolonged in the case of concurrent HIV infection. Thus, HIV-
infected subjects are more infectious and for a longer period than
non-HIV infected populations.5 The normalization of alanine
aminotransferase (ALT) levels may also be prolonged in these
patients.90 Moreover, chronic hepatitis C infection is more fre-
quent among HIV-infected subjects, and this pre-existing hepatic
infection could be linked to fulminant acute HAV.91
Hepatitis A vaccines for adults
The HAV vaccine is the most important preventive strat-
egy against HAV. The HAV vaccine first became available in
Europe in 1992 and in the United States in 1995.92,93 There
are currently 2 types of HAV vaccines: live attenuated and
formaldehyde inactivated vaccines. The latter are the most
widely used worldwide and are the only ones recommended
for HIV-infected subjects. There are several HAV vaccines
currently available. Most are adjuvanted with aluminum
hydroxide and there are presentations combined with other
vaccines (mainly with HBV and typhoid fever).94 In the
United States, 3 inactivated HAV vaccines are approved by
the FDA for adults: 2 single-antigen vaccines: Havrix 1440
(manufactured by GlaxoSmithKline) and VAQTA 50 (man-
ufactured by Merck & Co., Inc.). Twinrix (manufactured
by GlaxoSmithKline) contains both HAV (in a lower dosage)
and HBV antigens. 30 In Europe, only Twinrix has been
approved by the EMA for adults.31
Hepatitis A vaccines: efficacy and safety
HAV vaccine has been shown to be highly immunogenic
in the general population. From 90 to 95% of those vacci-
nated will have detectable protective antibodies one month
after 2 doses of an inactivated vaccine, and this may persist
for a few decades.88 Clinical trials in endemic countries have
shown a high protective efficacy against clinical hepatitis, usu-
ally above 90% one year after the last dose of vaccine.95,96
The effectiveness of the HAV vaccine has been shown by
marked reductions in disease incidence after the introduction
of vaccination. Reported declines in HAV incidence are usu-
ally above 90% 5–10 y after the introduction of childhood
immunization campaigns.97-99 The duration of protection has
been under study since these vaccines were introduced in the
1990s, but antibodies have been shown to persist for at least
17 y in almost all children vaccinated with 2 doses of inacti-
vated HAV vaccine in various studies.100-102 Some authors
have suggested that antibodies could persist for more than
45 y using a cut-off of 20 IU/L (the typical immunological
threshold used to determine vaccine response).103 The safety
profile of inactivated HAV vaccines (all types) has been
assessed in pre- and post- licensing trials and may be consid-
ered as excellent regardless of age at administration and the
scheduled used.88,104,105 Pain and tenderness are the most
common local adverse reactions at the injection site, occur-
ring in approximately 50% of recipients,88,106,107 whereas
fever and myalgias are the most common systemic adverse
events.107 No severe adverse events are usually reported fol-
lowing hepatitis A vaccination.
Immunological response after HAV vaccination in HIV-
infected adults: associated factors
There is little data on the efficacy of the HAV vaccine in HIV-
infected subjects, and the sample size of published studies is rela-
tively small in order to measure the reduction in attack rates in
vaccinated and unvaccinated populations. However, the immu-
nogenicity of the HAV vaccine in HIV-infected subjects has been
studied in populations with different characteristics, especially in
the HAART era.108-120 The evidence comes mainly from RCTs
and retrospective, observational studies. Table 3 shows studies
published in the HAART era that assessed the immunological
response to HAV (studies which measured the vaccine response
between 1 month and 1 y after the last dose). The heterogeneity
of the methodology and study populations means the results
must be interpreted with caution. The level of immunosuppres-
sion (measured by CD4 counts), the HIV RNA viral load, the
vaccine schedule and sex have been associated with the vaccine
response. HAV antibody seroconversion rates (after at least 2
doses of HAV vaccine) range from 48.5% to 93.9%.108,109 Thus,
the immune response to the HAV vaccine is reduced in immuno-
compromised patients (both the proportion of subjects who sero-
convert and the concentration of HAV antibody titres).111
A weakened immune system has been associated with a
poorer response to many vaccines121 and HAV is no exception.
Higher CD4 counts are associated with a better vaccine
response. 108,110,117,119,120 The cut-off CD4 count for a better
response differs between studies, but < 200 CD4 have been
associated with poorer antibody seroconversion in several stud-
ies.110,116-118,120 Rimland et al. reported that patients with
CD4 T-cell counts < 200 cells/mm3 were 16-times more likely
to be nonresponders.110 A lower CD4/CD8 ratio has also been
associated with a poorer response.119 Likewise, low HIV RNA
viral loads lead to better vaccine response in HIV-infected
adults.111,115
The number of HAV doses received affects the vaccine
response in HIV-infected patients. As in immunocompetent
individuals, 2 doses of hepatitis A vaccine are more immunogenic
than one.108,111,115,119,120 Studies comparing the vaccine
response according to whether recipients received 2 or 3 doses of
inactivated HAV vaccine found that both the proportion of res-
ponders and the GMT of HAV antibodies were higher after the
third dose.112,115 However, this seems not to be the case when
rapidly-accelerated schedules (day 0, 7 and 21) were used, at
www.tandfonline.com 2591Human Vaccines & Immunotherapeutics
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these were associated with a lower response in comparison with
patients receiving 2 doses of 6 months apart.119
Hepatitis C virus (HCV) coinfection was associated with a
lower probability of response.119 In fact, coinfection with the
HCV has been found to be a prognostic factor for non-
response to HAV vaccination in patients with CD4 counts <
200 cells/mm3.118 This association has also been described in
the case of HBV vaccination.122 Although more studies are
needed to elucidate the immune mechanisms explaining a
poorer vaccine response in HIV/HCV infected subjects, it
has been suggested that this co-infection results in dendritic
cell dysfunction that may impair antigen presentation and
thus affect the response to vaccination.
Sex has intermittently been associated with the vaccine
response in different studies. Three retrospective studies
reported that males were less likely to be respond-
ers,109,111,119 although Armstrong et al. reported an inverse
association.123 One study found that not smoking was associ-
ated with a better response to the HAV vaccine in HIV
infected adults,112 something already observed in immuno-
competent HBV vaccine recipients.124 The mechanisms
explaining the effect of smoking on the vaccine response
remain to be elucidated.
Long-term persistence of protective levels of IgG anti-VHA
Few studies have assessed the duration of protection provided
by HAV vaccination in HIV-infected adults. A retrospective
study by Crum-Cianflone et al. found that, in patients with well-
controlled HIV infections who responded to initial vaccination,
there was evidence of antibody persistence almost 10 y later
(90% after 3 y and 85% after 6–10 years).113 A prospective
study by Kerneis et al., showed persistence of antibodies in 85%
of patients after almost 4 y of follow up.125 Finally, a Polish
study by Jablonowska et al. found that 75% of HIV-infected
subjects who responded to initial vaccination had detectable anti-
bodies 5 y after vaccination.118 The duration of protection has
been associated with suppressed HIV RNA levels at
vaccination.113,125
Safety of HAV vaccination in HIV-infected adults
Limited data from randomized clinical trials is available on the
safety of HAV vaccines in HIV-infected patients.108,112,120,126,127
However, no serious adverse events are usually reported after
HAV vaccination regardless of the number of doses or the immu-
nological status,120 and vaccination has no effect on the course of
HIV infection.127 Adverse events are usually minor, although local
reaction at the injection site are frequently reported.108 The most
frequent local adverse events reported are pain and soreness. Mild
systemic events such as headache and fever have also been
reported.108 The frequency and nature of adverse events following
HAV vaccination is similar to placebo.120 Serious adverse events
following HIV vaccination in HIV-infected subjects have seldom
been reported.
Current recommendations on hepatitis A vaccination for
HIV-infected patients
Routine HAV vaccination of susceptible HIV-infected indi-
viduals is not widely accepted. Both the CDC and WHO recom-
mend vaccinating these subjects if any other medical, behavioral,
epidemiological or occupational condition is added to HIV infec-
tion.88,128 These conditions usually include: persons traveling to
or working in countries with high or intermediate HAV
endemicity, MSM, users of injectable drugs, persons with chronic
liver disease, including hepatitis B or C, people with clotting fac-
tor diseases, immunosuppressed persons who have undergone
transplantation, and contacts of children arriving from countries
with high or intermediate HAV endemicity. The US Guidelines
for prevention and treatment of opportunistic infections in HIV-
Infected adults and adolescents, BHIVA guidelines for the
immunization of HIV-infected adults and the clinical guidelines
of the EACS also support these recommendations.79,81
The currently-accepted global schedule is 2 doses separated by
6–12 months. In HIV patients considered at risk, the BHIVA
guidelines mention the option of vaccinating with a 3-dose
schedule administered within a maximum of 12 months, but
only in subjects with a CD4 lymphocyte count < 300 cells/
mm3.80
Of the institutional recommendations reviewed, only the UK
Green Book on immunisation against infectious diseases guid-
ance mentions revaccination when primary vaccination does not
produce a protective response.129
The EACS recommends periodic controls of antibody titres in
vaccinated immunocompromised subjects.81 The BHIVA recom-
mends a booster vaccine dose every 5 y (both bodies indicate vac-
cination in patients at risk of contracting hepatitis A).80
Concluding Remarks
The response to HBV and HAV vaccination is suboptimal in
HIV-infected subjects. The factors most frequently associated
with a deficient level of antibodies after vaccination are mainly
those related to immunosuppression (CD4 level and HIV RNA
viral load) and to the frequency of administration and/or the
amount of antigenic load in the doses. Furthermore, the studies
reviewed support the idea that the duration of the response is
worse than in HIV-free individuals. The duration of the response
to both HBV and HAV vaccines is associated with suppression of
the viral load at vaccination and, in the case of HBV vaccination,
is also associated with a higher antibody level after vaccination.
In terms of safety, there is no evidence of more, or different,
adverse effects compared with HIV-free individuals (Tables 2
and 3).
With respect to the indications for HBV vaccination in HIV-
infected adults, the default international recommendation
remains the administration of 3 doses at 0, 1 and 6 months. The
measures most frequently suggested in order to manage and
improve the response to vaccination are: starting HAART before
vaccination for patients with a CD4 cell count <200 cells/mm3
2594 Volume 11 Issue 11Human Vaccines & Immunotherapeutics
D
ow
nl
oa
de
d 
by
 [U
NI
VE
RS
IT
AT
 D
E 
BA
RC
EL
ON
A]
 at
 05
:41
 28
 Ja
nu
ary
 20
16
 
and ongoing HIV viral replication,81 serologic determination of
antibodies after administration of the last dose of vaccine, 79,80
re-vaccination when concentrations of anti-HBs of 10 IU/L are
not reached after primary vaccination,29,79,81 and annual serolog-
ical testing for those who have previously responded to
vaccination.79,80
Primary vaccination with a higher number of doses or a higher
concentration of HBsAg per dose has not been recommended by
any of the previously-mentioned institutions or associations.
In contrast to hepatitis B, routine HAV vaccination of suscep-
tible HIV-infected adults is not widely accepted. Both the CDC
and WHO recommend vaccinating these subjects if any other
medical, behavioral, epidemiological or occupational condition is
added to HIV infection.88,128 These conditions usually include:
persons traveling to or working in countries that have high or
intermediate HAV endemicity, MSM, injection drug users, per-
sons with chronic liver disease, including hepatitis B or C, people
with clotting factor diseases, immunosuppressed persons who
have undergone transplantation and contacts of children arriving
from countries with high or intermediate HAV endemicity. The
US Guidelines for prevention and treatment of opportunistic
infections in HIV-Infected adults and adolescents, the BHIVA
guidelines for the immunization of HIV-infected adults and the
clinical guidelines of the EACS also support these recommenda-
tions.79-81
In HIV-infected subjects who present any of the previously-
mentioned indications, the most widely recommended vaccina-
tion schedule is 2 doses separated by 6–12 months. Of the insti-
tutional recommendations reviewed, only the UK Green Book
on immunisation against infectious diseases guidance mentions
revaccination when primary vaccination does not produce a pro-
tective response.129 Periodic control of antibody titres in vacci-
nated immunocompromised subjects,81 the administration of a
booster dose every 5 years80 and vaccination with a 3-dose sched-
ule within a maximum of 12 months in subjects with a CD4
count <300 cells/mm3,80 are other strategies proposed for the
control and improvement of the response to HAV vaccination in
HIV-infected adults.
There is a substantial difference in the recommendations
made by the main associations and international health bodies
on the management of viral hepatitis vaccination in people living
with HIV. Despite literature-based advice with respect to the
administration of alternative schedules, revaccination after the
failure of primary vaccination, and the need for periodic re-evalu-
ation of antibody levels, few firm systematic recommendations
are found in the leading Guidelines. The large amount of scien-
tific literature on the subject of hepatitis vaccination in HIV-
infected subjects, especially HBV vaccination, should form the
basis of international consensual clinical guidelines that take into
account the diversity of patients living with HIV when adminis-
tering conventional vaccination or evaluating alternative ones
that may be useful in specific cases.
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